Skip to main content

Select Drug Profiles

Original Research, Rosacea, Dermatology
Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study
Todd Williamson, PhD, MSc, Wendy Y. Cheng, MPhil, MPH, Nora McCormick, MSc, Francis Vekeman, MA
Todd Williamson, PhD, MSc; Wendy Y. Cheng, MPhil, MPH; Nora McCormick, MSc; Francis Vekeman, MA
Stakeholder Perspective
There’s Room for Improvement in Rosacea Treatment
Gary M. Owens, MD
by Gary M. Owens, MD
Read More
Perspectives
20% by 2020
David B. Nash, MD, MBA
David B. Nash, MD, MBA
Read More
Review Article, Practice Management
Standardized Review and Approval Process for High-Cost Medication Use Promotes Value-Based Care in a Large Academic Medical System
Raghu Durvasula, MD, MHA, Janet Kelly, PharmD, Anneliese Schleyer, MD, MHA, Bradley D. Anawalt, MD, Shabir Somani, MS, MBA, RPh, FASHP, Timothy H. Dellit, MD
Raghu Durvasula, MD, MHA; Janet Kelly, PharmD; Anneliese Schleyer, MD, MHA; Bradley D. Anawalt, MD; Shabir Somani, MS, MBA, RPh, FASHP; Timothy H. Dellit, MD
Stakeholder Perspective
Pharmacy & Therapeutics Committees’ New Challenge: Stewardship for Specialty Drugs
Byron C. Scott, MD, MBA
by Byron C. Scott, MD, MBA
Read More
FDA Approvals, Payers' Guide
Welcome to the Ninth Annual Payers’ Guide to New FDA Approvals
Read More
FDA Approvals, Introduction, Payers' Guide
FDA Approvals in 2017 Represent a 21-Year High
Gary M. Owens, MD
Read More
FDA Approvals, Payers' Guide
FDA Approvals of Brand-Name Prescription Drugs in 2017
Read More
Payers' Guide, FDA Approvals
Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea
Loretta Fala
Read More
Payers' Guide, FDA Approvals
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Tremfya (Guselkumab), First-in-Class IL-23 Blocker, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis
Loretta Fala
Read More
Payers' Guide, FDA Approvals
Simponi Aria (Golimumab), the Only Fully Human Anti–TNF-α Infused Therapy, Now Approved for Active Psoriatic Arthritis and for Active Ankylosing Spondylitis
Lisa A. Raedler, PhD, RPh
Read More
Page 72 of 244
Results 711 - 720 of 2438